Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: J Addict Dis. 2013 Jan;32(1):68–78. doi: 10.1080/10550887.2012.759872

Table 4.

Clinical outcome at 24 weeks for completers

Buprenorphine n = 13 Methadone n = 13 OR 95% CI p
Retention in study, No. (%) 13/26 (50) 13/28 (46.4) 0.933 0.324–2.691 1.000
Percent change of pain from baseline, mean (SD) 87.4 (33.4) 88.6 (24.5) - - 0.918
Percent change of functioning from baseline, mean (SD) 121.9 (63.9) 113.8 (62.5) - - 0.787
Positive urine for opioids, No. (%) 5 (38.5) 2 (15.4) 0.280 0.042–1.878 0.371
Positive urine for cocaine, No. (%) 2 (15.4) 0 (0) - - 0.478
Positive urine for other drugs, No. (%) 5 (38.5) 5 (38.5) 1.000 0.197–5.068 1.000
Self-reported opioid use, No. (%) 5 (38.5) 0 (0) - - 0.039*
Self-reported alcohol use, No. (%) 4 (30.8) 2 (15.4) 0.409 0.060–2.769 0.645
Self-reported use of other drugs, No. (%) 5 (38.5) 3 (23.1) 0.480 0.087–2.645 0.673
Self-reported side effects, No. (%) 8 (61.5) 9 (69.2) 1.125 0.209–6.046 1.000
*

p-value: α < 0.05